Low dopamine D2 receptor binding in subregions of the thalamus in schizophrenia

American Journal of Psychiatry

Volumn 161, Issue 6, 2004, Pages 1016-1022

  Yasuno, Fumihiko ^b   Suhara, Tetsuya ^a   Okubo, Yoshiro ^b   Sudo, Yasuhiko ^b   Inoue, Makoto ^b   Ichimiya, Tetsuya ^b   Takano, Akihiro ^b   Nakayama, Kazuhiko ^b   Halldin, Christer ^b   Farde, Lars ^b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE; DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE; RADIOLIGAND;

ADULT; ARTICLE; BINDING ASSAY; BINDING KINETICS; BRAIN REGION; CALCULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULVINAR; RATING SCALE; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM; TECHNIQUE; THALAMUS; THALAMUS DORSOMEDIAL NUCLEUS;

ADULT; BRIEF PSYCHIATRIC RATING SCALE; CARBON RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PYRROLIDINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THALAMIC NUCLEI; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2942615018     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.6.1016     Document Type: Article

References (57)

1. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L: Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002; 59:25-30
2. Andreasen NC, Arndt S, Swayze V II, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WTC: Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994; 266:294-298
3. Andreasen NC, Ehrhardt JC, Swayze VW II, Alliger RJ, Yuh WT, Cohen G, Ziebell S: Magnetic resonance imaging of the brain in schizophrenia: the pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry 1990; 47:35-44
4. Pakkenberg B: The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophr Res 1992; 7:95-100
5. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A, Haier RJ, Wu J, Bunney WE Jr: PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 1996; 153:191-199
6. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155:1711-1717
7. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS: Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 2001; 158:618-624
8. Byne W, Buchsbaum MS, Kemether E, Hazlett EA, Shinwari A, Mitropoulou V, Siever LJ: Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry 2001; 58:133-140
9. Ananth H, Popescu I, Critchley HD, Good CD, Frackowiak RSJ, Dolan RJ: Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 2002; 159:1497-1505
10. Rodriguez VM, Andree RM, Castejon MJ, Zamora ML, Alvaro PC, Delgado JL, Vila FJ: Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients: a 99mTc-HMPAO study. Psychiatry Res 1997; 76:51-61
11. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA: Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996; 153:41-49
12. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN: Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res 1998; 83:105-115
13. Gunther W: MRI-SPECT and PET-EEG findings on brain dysfunction in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:445-462
14. Pakkenberg B: Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990; 47:1023-1028
15. Young KA, Manaye KF, Liang C, Hicks PB, German DC: Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000; 47:944-953
16. Popken GJ, Bunney WE Jr, Potkin SG, Jones EG: Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 2000; 97:9276-9280
17. Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL, Purohit DP, Haroutunian V, Jones L: Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 2002; 159:59-65
18. Blennow K, Bogdanovic N, Heilig M, Grenfeldt B, Karlsson I, Davidsson P: Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. J Neural Transm 2000; 107:1085-1097
19. Ungerstedt U: Stereotaxic mapping of monoamine pathways in the rat brain. Acta Physiol Scand 1971; 367:1-48
20. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA, Schmidt DE, Mason NS, Manning RG: Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 1993; 609:237-243
21. Langer O, Halldin C, Dolle F, Swahn CG, Olsson H, Karlsson P, Hall H, Sandell I, Lundkvist C, Vaufrey F, Loc'h C, Crouzel C, Maziere B, Farde L: Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. Nucl Med Biol 1999; 26:509-518
22. Sedvall G, Farde L: Chemical brain anatomy in schizophrenia. Lancet 1995; 346:743-749
23. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L: Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 1999; 2:73-82
24. Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, Farde L: PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. Neuroimage 1999; 10:666-674
25. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C: A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997; 133:396-404
26. Jones EG: The Thalamus. New York, Plenum, 1985
27. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG: Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36:1275-1281
28. Kitamura T, Machizawa S, Maruyama S, Nakagawa Y, Morita M, Sato T: Test-retest reliability of Oxford University version of the Brief Psychiatric Rating Scale (BPRS): a preliminary survey of multicenter collaborative study initiated by the National Institute of Mental Health. J Ment Health 1985; 32:1-15
29. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
30. Lammertsma AA, Hume S: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-158
31. Olsson H, Halldin C, Swahn CG, Farde L: Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999; 19:1164-1173
32. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15:217-227
33. Yasuno F, Hasnine AH, Suhara T, Ichimiya T, Sudo Y, Inoue M, Takano A, Ou T, Ando T, Toyama H: Template-based method for multiple volumes of interest of human brain PET images. Neuroimage 2002; 16:577-586
34. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ: Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2:189-210
35. Studholme C, Hill DL, Hawkes DJ: Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24:25-35
36. Oke AF, Adams RN: Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia. Schizophr Bull 1987; 13:589-604
37. Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K: Effect of endogenous dopamine on extrastriatal [11C]FLB 457 binding measured by PET. Synapse 2001; 41:87-95
38. Goldsmith SK, Shapiro RM, Joyce JN: Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. Arch Gen Psychiatry 1997; 54:649-658
39. Carlsson A, Waters N, Waters S, Carlsson ML: Network interactions in schizophrenia-therapeutic implications. Brain Res Brain Res Rev 2000; 31:342-349
40. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL: Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry 2002; 159:1375-1381
41. Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Germans MK, Schnur DB, Jimenez EA, Buchsbaum BR, Troyer BT: Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 1998; 35:186-198
42. Kodsi MH, Swerdlow NR: Regulation of prepulse inhibition by ventral pallidal projections. Brain Res Bull 1997; 43:219-228
43. Young KA, Randall PK, Wilcox RE: Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents. Neuroreport 1995; 6:2495-2499
44. Jones EG: Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997; 23:483-501
45. Robinson DL, Petersen SE: The pulvinar and visual salience. Trends Neurosci 1992; 15:127-132
46. LaBerge D, Buchsbaum MS: Positron emission tomographic measurements of pulvinar activity during an attention task. J Neurosci 1990; 10:613-619
47. Morris JS, Friston KJ, Dolan RJ: Neural responses to salient visual stimuli. Proc R Soc Lond B Biol Sci 1997; 264:769-775
48. Romanski LM, Giguere M, Bates JF, Goldman-Rakic PS: Topographic organization of medial pulvinar connections with the prefrontal cortex in the rhesus monkey. J Comp Neurol 1997; 379:313-332
49. Vogt BA, Pandya DN, Rosene DL: Cingulate cortex of the rhesus monkey, I: cytoarchitecture and thalamic afferents. J Comp Neurol 1987; 262:256-270
50. Vogt BA, Pandya DN: Cingulate cortex of the rhesus monkey, II: cortical afferents. J Comp Neurol 1987; 262:271-289
51. Vita A, Bressi S, Perani D, Invernizzi G, Giobbio GM, Dieci M, Garbarini M, Del Sole A, Fazio F: High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am J Psychiatry 1995; 152:876-882
52. Portas CM, Goldstein JM, Shenton ME, Hokama HH, Wible CG, Fischer I, Kikinis R, Donnino R, Jolesz FA, McCarley RW: Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging. Biol Psychiatry 1998; 43:649-659
53. Saijo T, Abe T, Someya Y, Sassa T, Sudo Y, Suhara T, Shuno T, Asai K, Okubo Y: Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin Neurosci 2001; 55:41-47
54. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347:146-151
55. Landwehrmeyer B, Mengod G, Palacios JM: Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 1993; 18:187-192
56. Murray AM, Ryoo HL, Gurevich E, Joyce JN: Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994; 91:11271-11275
57. Welham J, Stedman T, Clair A: Choosing negative symptom instruments: issues of representation and redundancy. Psychiatry Res 1999; 87:47-56